CULLINAN THERAPEUTICS, INC. (CGEM) Current Ratio
- Current ratio · latest quarter: Value 8.42×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.42× | Current assets / current liabilities. $341.97M ÷ $40.63M ≈ 8.42× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 341.97M USD | Assets, Current |
| Current obligations | 40.63M USD | Liabilities, Current |
| Cash and equivalents | 78.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.73M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $341.97M | $40.63M | $78.64M | (m) | (m) | (m) | $3.73M | (m) | 8.42× |
| 2026-03-31 | $361.41M | $35.15M | $75.08M | (m) | (m) | (m) | $2.51M | (m) | 10.28× |
| 2025-12-31 | $386.76M | $37.74M | $88.33M | (m) | (m) | (m) | $841.00K | (m) | 10.25× |
| 2025-09-30 | $342.24M | $32.76M | $103.33M | (m) | (m) | (m) | $1.72M | (m) | 10.45× |
| 2025-06-30 | $275.91M | $28.06M | $72.82M | (m) | (m) | (m) | $2.46M | (m) | 9.83× |
| 2025-03-31 | $317.77M | $27.35M | $76.66M | (m) | (m) | (m) | $3.40M | (m) | 11.62× |
| 2024-12-31 | $414.67M | $30.65M | $83.00M | (m) | (m) | (m) | $1.68M | (m) | 13.53× |
| 2024-09-30 | $592.04M | $24.20M | $102.08M | (m) | (m) | (m) | $2.12M | (m) | 24.46× |
| 2024-06-30 | $677.80M | $23.48M | $115.02M | (m) | (m) | (m) | $1.55M | (m) | 28.87× |
| 2024-03-31 | $445.72M | $21.93M | $74.23M | (m) | (m) | (m) | $3.71M | (m) | 20.33× |
| 2023-12-31 | $480.19M | $28.14M | $98.43M | (m) | (m) | (m) | $2.49M | (m) | 17.07× |
| 2023-09-30 | $476.71M | $23.44M | $64.85M | (m) | (m) | (m) | $951.00K | (m) | 20.33× |
| 2023-06-30 | $498.24M | $19.68M | $141.83M | (m) | (m) | (m) | $2.49M | (m) | 25.32× |
| 2023-03-31 | $399.03M | $26.17M | $122.13M | (m) | (m) | (m) | $2.03M | (m) | 15.25× |
| 2022-12-31 | $474.47M | $22.50M | $156.15M | (m) | (m) | (m) | $2.66M | (m) | 21.09× |
| 2022-09-30 | $582.08M | $27.12M | $242.66M | (m) | (m) | (m) | $1.52M | (m) | 21.47× |
| 2022-06-30 | $622.84M | $62.03M | $353.56M | (m) | (m) | (m) | $3.10M | (m) | 10.04× |
| 2022-03-31 | $322.31M | $17.26M | $76.12M | (m) | (m) | (m) | $6.31M | (m) | 18.68× |
| 2021-12-31 | $296.56M | $11.75M | $59.77M | (m) | (m) | (m) | $3.17M | (m) | 25.25× |
| 2021-09-30 | $328.84M | $7.86M | $88.11M | (m) | (m) | (m) | $2.02M | (m) | 41.82× |
| 2021-06-30 | $344.47M | $5.74M | $123.67M | (m) | (m) | (m) | $1.51M | (m) | 59.98× |
| 2021-03-31 | $447.29M | $9.89M | $293.54M | (m) | (m) | (m) | $3.88M | (m) | 45.21× |
| 2020-12-31 | $212.28M | $14.32M | $168.20M | (m) | (m) | (m) | $9.68M | (m) | 14.82× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |